Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers.

ESMO Real World Data Digit Oncol · 2024 · PMC12836636 · PMID 41646105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Despite similar OS, nonclass 1 mutant tumors showed a trend toward lower PFS with BRAF/MEK blockade.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.